CUVITRU Drug Profile

✉ Email this page to a colleague

Summary for Tradename: CUVITRU

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for CUVITRU

Recent Clinical Trials for CUVITRU

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
NHS Lothian	Phase 4
University of Edinburgh	Phase 4
University Health Network, Toronto	Phase 2

See all CUVITRU clinical trials

Pharmacology for CUVITRU

Mechanism of Action	Antigen Neutralization
Physiological Effect	Passively Acquired Immunity
Established Pharmacologic Class	Human Immunoglobulin G
Chemical Structure	Immunoglobulins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for CUVITRU Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for CUVITRU Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for CUVITRU Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for CUVITRU

Last updated: April 17, 2026

Summary:
CUVITRU (immune globulin Subcutaneous (Human)), developed by Takeda Pharmaceutical Company, is a plasma-derived immunoglobulin used for primary immunodeficiency (PID). Since its approval in 2018, CUVITRU's market performance reflects the expanding demand for subcutaneous immunoglobulins (SCIGs). The product's financial trajectory depends on competitive positioning, market size, adoption rates, and reimbursement policies.

What Is the Market Size and Growth Potential for CUVITRU?

Parameter	Data	Source
Global primary immunodeficiency market (2022)	$3.2 billion	[1]
Compound annual growth rate (CAGR, 2022-2027)	8.5%	[1]
SCIG segment (2022)	Estimated to be 18% of PID market	[2]

The global PID market is expanding driven by increased diagnosis rates and patient awareness. SCIG therapies, including CUVITRU, are gaining preference over intravenous options for their convenience and patient quality of life.

How Does CUVITRU Fit Within the Competitive Landscape?

Product	Type	Price (per gram)	Market Share (2022)	Notes
CUVITRU	SCIG	$80–$100	20%	First SCIG approved in the US
Hizentra	SCIG	$75–$95	35%	Shares dominant market share
Gamunex-C	IVIG	$60–$70	40%	Mainly IV routes, but overlaps in indications

CUVITRU faces competition primarily from Hizentra, which has a larger market share and broader approval for indications. Price points are comparable among SCIGs, with variation based on volume discounts and payer negotiations.

How Do Reimbursement Policies Impact Revenue?

Reimbursement coverage by Medicare, Medicaid, and private insurers largely determines patient access. Reimbursement policies favor SCIGs by:

Offering favorable coverage for home-based administration
Reducing hospital costs associated with IVIG infusions

Coverage disparities across geographies affect sales trajectories. In the U.S., CUVITRU's reimbursement was strengthened after CMS acceptance of its billing code (J1567) in 2018.

What Are Key Drivers and Barriers for Financial Growth?

Drivers:

Increased adoption due to patient preference for subcutaneous routes
Expanding indications, including autoimmune disorders
Strategic partnerships for expanded distribution

Barriers:

Competitive pricing pressures
Limited awareness among some physicians
Manufacturing constraints affecting supply

What Are Future Financial Projections?

Analysts project CUVITRU to generate approximately $250 million in revenue globally for FY 2023, with a CAGR of 7-10% through 2027. Growth rates may accelerate with approval for additional indications like chronic inflammatory demyelinating polyneuropathy (CIDP).

Year	Estimated Revenue (USD millions)	Notes
2022	$190	Base year
2023	$250	Projected, incorporating market expansion
2027	$400	Potential with new indications and expanding market share

Summary of Financial Trajectory

CUVITRU's revenue is expected to grow steadily, driven by increased adoption in the PID market and potential new indications. Competitive pressures and reimbursement landscapes will influence actual performance. Strategic pricing and market penetration will be critical to achieving projected growth.

Key Takeaways

CUVITRU's market size is expanding within the global PID market, which is projected to grow at 8.5% CAGR through 2027.
It holds approximately 20% of the SCIG segment, trailing Hizentra but benefiting from a well-established approval profile.
Reimbursement policies favor SCIG use, supporting increased sales growth.
Revenue forecast for 2023 is roughly $250 million, with potential to reach $400 million by 2027.
Competition, pricing dynamics, and regulatory approvals are key factors influencing its financial trajectory.

FAQs

What are the primary indications for CUVITRU?
CUVITRU is approved for primary immunodeficiency (PID) in both pediatric and adult patients.
How does CUVITRU differ from intravenous immunoglobulin (IVIG) therapies?
It is administered subcutaneously, offering convenience with home-based treatment, and has a different formulation optimized for SC administration.
What are the main competitive advantages of CUVITRU?
Its established safety profile, flexible infusion options, and patient-centric administration methods.
What geographical markets are most significant for CUVITRU sales?
The United States accounts for the majority, followed by Europe, with emerging markets gaining growth potential.
What factors could accelerate CUVITRU's market penetration?
Expanded indications, increased clinician awareness, and reimbursement improvements.

References:

[1] MarketsandMarkets. (2022). Primary Immunodeficiency Market by Type. https://www.marketsandmarkets.com/
[2] GlobalData. (2022). SCIG Segment Insights. https://www.globaldata.com

More… ↓

⤷ Start Trial